Search
Tavaborole
go.drugbank.com/drugs/DB09041ApprovedTavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes … Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).
Synonyms: 5-Fluoro-2,1-benzoxaborol-1(3H)-olOmega-3-carboxylic acids
go.drugbank.com/drugs/DB09568ApprovedWithdrawnThe omega-3 carboxylic acid (OM3-CA) is a new formulation of omega-3 fatty acids that present an enhanced bioavailability in the treatment of dyslipidemia. … It is a complex mixture of the free fatty acids form containing eicosapentaenoic acid and docosahexaenoic acid as the most abundant species found in a proportion of 55% and 20% respectively.
Anthralin
go.drugbank.com/drugs/DB11157ApprovedAnthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. … Anthralin is also known as dithranol. It is a main active ingredient in topical skin formulations for the treatment of psoriasis.
Dexbrompheniramine
go.drugbank.com/drugs/DB00405ApprovedDexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria.
Mixtures: Supress A, M-end Max DSynonyms: d-brompheniramineCholic Acid
go.drugbank.com/drugs/DB02659ApprovedInvestigational[PubChem] Cholic acid, formulated as Cholbam capsules, is approved by the United States Food and Drug Administration as a treatment for children and adults with bile acid synthesis disorders due to single … A major primary bile acid produced in the liver and usually conjugated with glycine or taurine. It facilitates fat absorption and cholesterol excretion.
Niclosamide
go.drugbank.com/drugs/DB06803ApprovedInvestigationalVet approvedNiclosamide is an antihelminthic used for the treatment of tapeworm infections. … Helminths (worms) are multicellular organisms that infect very large numbers of humans and cause a broad range of diseases.
Categories: Compounds used in a research, industrial, or household settingSomatrogon
go.drugbank.com/drugs/DB14960ApprovedInvestigational[L39362] In October 2021, Health Canada approved somatrogon under the market name NGENLA as the long-term treatment of pediatric patients who have growth failure due to an inadequate secretion of endogenous … It is a chimeric product generated by fusing three copies of the C-terminal peptide (CTP), or 28 carboxy-terminal residues, from the beta chain of human chorionic gonadotropin (hCG) to the N-terminus and
Synonyms: HUMAN GROWTH HORMONE-CARBOXY-TERMINAL PEPTIDE (CTP) OF THE BETA CHAIN OF HUMAN CHORIONIC GONADOTROPIN FUSION PROTEIN, FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA.Trolamine
go.drugbank.com/drugs/DB13747ApprovedInvestigationalTrolamine contains small amounts of diethanolamine and ethanolamine and may also act as an antioxidant against the auto-oxidation of animal and vegetable fats [A27174]. … Trolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines.
Categories: Preparations for Treatment of Wounds and UlcersMCC
go.drugbank.com/drugs/DB05282InvestigationalThe product is a sterile biological composition in a sub-micron suspension. It is produced at the Bioniche manufacturing facility in Pointe-Claire, Quebec. … Mycobacterial Cell Wall-DNA Complex (MCC) is formulated from Mycobacterium phlei, a non-pathogenic strain of mycobacteria.
Baloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[A39895, A251755] It is a prodrug of [baloxavir] [L42855] with an improved absorption profile than its active metabolite due to the addition of a phenolic hydroxyl group to its structure. … [L4779] It was also approved by the European Commission on January 7, 2021.[L45241]